Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
A phase 1/2 trial of Olaparib in advanced solid tumours, run by Artios Pharma Ltd, now recruiting.
Overview
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) is a phase 1/2 interventional study registered as NCT05898399 by Artios Pharma Ltd, with 181 participants planned, started 2023-06-30 and due to reach its primary completion in 2028-06-30. Interventions recorded: ART6043 and Olaparib.
Similar pages
not linked directly; found by shared links- TrialEIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Shares Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.